Patent intelligence · US
US 6150325
Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compositions
Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compositions
Patent details — US 6150325
- Jurisdiction
- US
- Status
- expired
- Grant date
- Nov 21, 2000
- Expiration
- Nov 16, 2020
- Applicant
- MENARINI FARMA IND [IT]
- CPC classes
- A61K 38/ 00 A I, A61K 38/ 12 A I, A61P 1/ 00 A I, A61P 9/ 00 A I
Quick answer
US 6150325 (Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compositions) is held by MENARINI FARMA IND [IT]. Status: expired. Granted Nov 21, 2000. Expires Nov 16, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MENARINI FARMA IND [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 00 A I, A61K 38/ 12 A I, A61P 1/ 00 A I, A61P 9/ 00 A I, A61P 9/ 12 A I, A61P 11/ 00 A I
More from MENARINI FARMA IND [IT]
Related pharmaceutical patents in our USPTO index.
-
IT 201700031902
Composizione nutraceutica, dietetica e nutrizionale ad attività antiossidante.
granted -
CA 2682039
PREPARATIONS COSMETIQUES VISANT A REDUIRE LA CELLULITE DISGRACIEUSE
granted -
EP 1526849
TOPISCHE ZUSAMMENSETZUNG ENTHALTEND KETOPROFEN STABILISIERT MIT SULISOBENZON
expired -
AT E203027
PENEMDERIVATE, DEREN HERSTELLUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
expired
Frequently asked questions
What is US patent 6150325?
US 6150325 (Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compositions) is held by MENARINI FARMA IND [IT]. Status: expired. Granted Nov 21, 2000. Expires Nov 16, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6150325?
MENARINI FARMA IND [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 6150325 expire?
Our index shows an expiration date of Nov 16, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.